The importance and pitfalls of correlational science in palliative care research

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 4, 2012, Pages 508-513

  Klepstad, Pal ^a,b   Kaasa, Stein ^a,c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Correlational science; Palliative care; Research methodology

Indexed keywords

BIOLOGICAL MARKER;

CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; HUMAN; METHODOLOGY; PALLIATIVE THERAPY; REVIEW; STATISTICAL ANALYSIS; STATISTICS;

BIOLOGICAL MARKERS; CAUSALITY; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; HUMANS; PALLIATIVE CARE; RESEARCH DESIGN; STATISTICS AS TOPIC;

EID: 84871189871     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32835a0c70     Document Type: Review

References (13)

1. Jiminez A, Madero R, Alonso A, et al. Symptom clusters in advanced cancer. J Pain Symptom Manage 2011; 42:24-31.
2. Laird BJA, Scott AC, Colvin LA, et al. Pain, depression, and fatigue as a symptom cluster in advanced cancer. J Pain Symptom Manage 2011; 42:1-11.
3. Hutchinson MR, Shavit Y, Grace PM, et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 2011; 63:772-810.
4. Kim H, Clark D, Dionne RA. Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J Pain 2009; 10:663-693.
5. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8:887-899.
6. Knudsen AK, Brunelli C, Kaasa S, et al. Which variables are associated with pain intensity and treatment response in advanced cancer patients? Implications for a future classification system for cancer pain. Eur J Pain 2011; 15:320-327.
7. Kaasa S, Apolone G, Klepstad P, et al. Expert conference on cancer pain assessment and classification-the need for international consensus: working proposals on international standards. BMJ Support Palliat Care 2011; 1:281-287.
8. Lotsch J, Skarke C, Grosch S, et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of mor-phine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12:3-9.
9. Angst MS, Phillips NG, Drover DR, et al. Pain sensitivity and opioid analgesia: a pharmacogenomic twin study. Pain 2012; 153:1397-1409.
10. Oertel BG, Preibisch C, Wallenhorst T, et al. Differential opioid action on sensory and affective cerebral processing. Clin Pharmacol Ther 2008; 83:577-588.
11. Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011; 152:1139-1145.
12. Ederoth P, Tunblad K, Bouw R, et al. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol 2004; 57:427-435.
13. Abbadie C, Pan YX, Pasternak GW. Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR-1C-like and MOR-1-like immunoreactivity: evidence for region-specific processing. J Comp Neurol 2000; 419:244-256.